Results 11 to 20 of about 54,104 (311)
Signal Transduction and Targeted Therapy, 2021 Thalidomide induces γ-globin expression in erythroid progenitor cells, but its efficacy on patients with transfusion-dependent β-thalassemia (TDT) remains unclear.
Jiang-Ming Chen +30 more
doaj +2 more sources
Treatment of pyoderma gangrenosum with thalidomide in a myelodysplastic syndrome case
International Medical Case Reports Journal, 2016 Umit Yavuz Malkan, Gursel Gunes, Eylem Eliacik, Ibrahim Celalettin Haznedaroglu Department of Hematology, School of Medicine, Hacettepe University, Ankara, Turkey Abstract: Thalidomide may be used as a treatment option for pyoderma gangrenosum (PG) and ...
Malkan UY +3 more
doaj +2 more sources
Thalidomide-induced Bradycardia in an Old Man
International Journal of Gerontology, 2010 We presented a case of an 82-year-old man who had classic Kaposi sarcoma. He took thalidomide 100 mg twice daily for 23 days, and then he felt light-headedness and visited our emergency department.
Ching-Hsueh Tseng +2 more
doaj +2 more sources
Chemical Society Reviews, 2022 Progress in strategies aimed at breaking down therapeutic target proteins has led to a paradigm shift in drug discovery. Thalidomide and its derivatives are the only protein degraders currently used in clinical practice.
Junichi Yamamoto +3 more
semanticscholar +1 more source
Frontiers in Pharmacology, 2022 At present, the main therapies for ß-thalassemia patients include regular blood transfusion and iron chelation, associating with a number of limitations.
Yanfei Lu +4 more
semanticscholar +1 more source
EMBO Journal, 2021 Thalidomide causes teratogenic effects by inducing protein degradation via cereblon (CRBN)‐containing ubiquitin ligase and modification of its substrate specificity.
S. Yamanaka +11 more
semanticscholar +1 more source
Thalidomide attenuates nitric oxide mediated angiogenesis by blocking migration of endothelial cells
BMC Cell Biology, 2006 Background Thalidomide is an immunomodulatory agent, which arrests angiogenesis. The mechanism of anti-angiogenic activity of thalidomide is not fully understood.
Indhumathy M +5 more
doaj +1 more source
Thalidomide inhibits alternative activation of macrophages in vivo and in vitro: a potential mechanism of anti-asthmatic effect of thalidomide. [PDF]
PLoS ONE, 2015 Thalidomide is known to have anti-inflammatory and immunomodulatory actions. However, the effect and the anti-asthmatic mechanism of thalidomide in the pathogenesis of asthmatic airways are not fully understood.This study is designed to determine the ...
Hyun Seung Lee +9 more
doaj +1 more source
Thalidomide: history, withdrawal, renaissance, and safety concerns
Expert Opinion on Drug Safety, 2021 Thalidomide was marketed as a safe and effective sedative beginning in 1957 and was later found to be effective at treating morning sickness. It was believed to be so safe that it was available over the counter in several countries.
N. Vargesson, T. Stephens
semanticscholar +1 more source
Journal of Hematology & Oncology, 2010 Background Thalidomide based regimen is an effective and well tolerated therapy in multiple myeloma (MM) patients, however, there were a small number of studies written about the results of thalidomide therapy in non-transplant MM patients.
Aungchaisuksiri Pantep +7 more
doaj +1 more source